Increased levels of circulating islet amyloid polypeptide in patients with chronic renal failure have no effect on insulin secretion.
Authors:
- A Kautzky-WillerA Kautzky-Willer
- E HartterEHE Hartter
- G PaciniGPG Pacini
Open Access
- 1 November 1994
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 94 (5) , 2045-2050
Abstract
To elucidate the metabolism of islet amyloid polypeptide (IAPP) with respect to a possible renal elimination we investigated IAPP levels in 20 lean, nondiabetic patients with renal failure maintained on chronic hemodialysis (HD) and in 20 healthy controls. The basal levels of IAPP were significantly higher in uremic patients than in controls (15.1 +/- 3.2 vs. 3.2 +/- 0.2 pM, P < 0.001) suggesting renal excretion of IAPP. To investigate the impact of chronically elevated levels of endogenous IAPP on insulin secretion and insulin sensitivity, a frequently sampled intravenous glucose tolerance test (FSIGT) was performed in a subset of patients on hemodialysis and in age-matched healthy controls (C) and obese patients with normal (NGT) and with impaired glucose tolerance (IGT). Insulin sensitivity index (SI) was 8.7 +/- 1.5 in C (P < 0.05 vs. NGT, P < 0.01 vs. IGT), 5.4 +/- 0.9 in HD (P < 0.05 vs. IGT), 3.1 +/- 1.0 in NGT, and 2.0 +/- 0.5 in IGT. First phase insulin secretion was increased in patients on HD compared with those of several control groups. The results of this study therefore indicate a renal route of metabolism of IAPP. Increased endogenous circulating IAPP levels over a long period of time do not lead to a decrease in insulin release in patients on HD and do not cause the insulin resistance commonly seen in obesity and diabetes. Increased levels of circulating IAPP therefore are not likely to be a pathogenetic factor in the development of non-insulin-dependent diabetes mellitus (NIDDM).Keywords
This publication has 27 references indexed in Scilit:
- Human islet amyloid polypeptide transgenic mice as a model of non‐insulin‐dependent diabetes mellitus (NIDDM)FEBS Letters, 1993
- Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle.Proceedings of the National Academy of Sciences, 1988
- Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitroNature, 1988
- Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients.Proceedings of the National Academy of Sciences, 1987
- ISLET AMYLOID FORMED FROM DIABETES-ASSOCIATED PEPTIDE MAY BE PATHOGENIC IN TYPE-2 DIABETESThe Lancet, 1987
- A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreasBiochemical and Biophysical Research Communications, 1986
- MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance testComputer Methods and Programs in Biomedicine, 1986
- In vivo kinetics of insulin action on peripheral glucose disposal and hepatic glucose output in normal and obese subjects.Journal of Clinical Investigation, 1986
- Glucose metabolism and insulin sensitivity in patients on chronic hemodialysisMetabolism, 1985
- Role of parathyroid hormone in the glucose intolerance of chronic renal failure.Journal of Clinical Investigation, 1985